Hirano Genryu, Sakurai Kunitoshi, Sohda Tetsuro, Kunimoto Hideo, Yotsumoto Kaoru, Fukunaga Atsushi, Iwashita Hideyuki, Ueda Shuichi, Yokoyama Keiji, Morihara Daisuke, Takeyama Yasuaki, Sakamoto Masaharu, Irie Makoto, Iwata Kaoru, Shakado Satoshi, Sakisaka Shotaro
Department of Gastroenterology and Medicine, Fukuoka University Faculty of Medicine, Fukuoka, Japan.
Hepatogastroenterology. 2012 Oct;59(119):2264-8. doi: 10.5754/hge12030.
BACKGROUND/AIMS: We have evaluated the effectiveness of systemic chemotherapy for patients with extrahepatic metastasis from hepatocellular carcinoma.
We examined the background, survival rates, median survival time and side effects of 15 cases in which systemic chemotherapy using carboplatin and 5-fluorouracil was done (chemotherapy group) and 59 cases in which chemotherapy was not done (non-chemotherapy group) out of a total of 74 cases of patients with extrahepatic metastasis from hepatocellular carcinoma.
The prognoses of the 15 chemotherapy cases and the 59 non-chemotherapy cases were as follows: 66.0%, 33.3%, 20.0% at 6 months, 12 months, 18 months respectively for the chemotherapy cases and 44.0%, 18.2%, 7.1% respectively for the non-chemotherapy cases. Median survival periods were 10.7 months for the chemotherapy group and 5.1 months for the non-chemotherapy group. A significantly better prognosis of survival (p=0.037) was identified in the chemotherapy group and no serious side effects were observed.
The present research preceded the approval of sorafenib. This systemic combination chemotherapy will provide an extended survival prognosis and is thus considered to be comparatively safe and effective in those patients.
背景/目的：我们评估了全身化疗对肝细胞癌肝外转移患者的疗效。
我们研究了74例肝细胞癌肝外转移患者中，15例行卡铂和5-氟尿嘧啶全身化疗的患者（化疗组）以及59例未进行化疗的患者（非化疗组）的背景、生存率、中位生存时间和副作用。
15例化疗患者和59例非化疗患者的预后如下：化疗组6个月、12个月、18个月的生存率分别为66.0%、33.3%、20.0%，非化疗组分别为44.0%、18.2%、7.1%。化疗组的中位生存期为10.7个月，非化疗组为5.1个月。化疗组的生存预后明显更好（p = 0.037），且未观察到严重副作用。
本研究早于索拉非尼获批。这种全身联合化疗将延长生存预后，因此被认为对这些患者相对安全有效。
